Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
Open Access
- 26 April 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 23 (6) , 1049-1052
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of MortalityCirculation, 2018
- Potassium and the Use of Renin–Angiotensin–Aldosterone System Inhibitors in Heart Failure with Reduced Ejection Fraction: Data from BIOSTAT-CHFEuropean Journal of Heart Failure, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Associations of serum potassium levels with mortality in chronic heart failure patientsEuropean Heart Journal, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled AnalysisDiabetes Therapy, 2016
- Regulation of Potassium HomeostasisClinical Journal of the American Society of Nephrology, 2015
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)Current Medical Research and Opinion, 2014
- Mechanism of Hypokalemia in Magnesium DeficiencyJournal of the American Society of Nephrology, 2007